FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Chevron, and More
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Pharmaceutical Technology21m
NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...
Erie News Now27m
5 Things to know for Jan. 31: Plane collision, Confirmation hearings, Pain medicine, Japan sinkhole, FireAid benefit concerts
Here’s what else you need to know to Get Up to Speed and On with Your Day. Three of President Donald Trump’s most controversial picks for his Cabinet and key administration roles were grilled during ...
pharmaphorum23m
Exploring the future: Opportunities and challenges in cell and gene therapy for rare diseases
In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...
North American Morning Briefing: Investors in -2-
A midair collision between an American Airlines flight and an Army helicopter over the Potomac River killed all 67 people on the two aircraft, officials said Thursday, leaving investigators to piece ...